• Sapien 3 Ultra; Low-Risk TAVR; Pivoting Bioresorbable Tech

    Interventional cardiology news to note

    Edwards Lifesciences announced that its Sapien 3 Ultra got Europe's CE Mark for transcatheter aortic valve replacement (TAVR) in severe, symptomatic aortic stenosis patients. The Ultra model uses a new delivery system and sheath and adds an "on balloon" design that makes valve alignment unnecessary, the press release said.

    TAVR was better than surgery for short-term survival among low-risk patients with a Society of Thoracic Surgeons score under 4%, according to the German registry. (European Heart Journal)

    What do you do in the cath lab when someone presents with an acute MI due to saphenous vein graft failure and has a chronic total occlusion in the native coronary artery supplied? Staged revascularization, one group suggested with a two-case series. (Catheterization and Cardiovascular Interventions)

    Among older acute MI patients in the ACTION registry, frail individuals were less likely to undergo cardiac catheterization but the ones that did experienced more in-hospital bleeding, according to a report in JACC: Cardiovascular Interventions. There was no such bleeding disadvantage for these patients getting conservative management, however. See MedPage Today's full coverage here.

    The Tyrocore polymer used in Reva's Fantom bioresorbable scaffold is being used to develop embolic microbeads to target liver cancer, uterine fibroids, and benign prostatic hyperplasia, the company announced.

    Bail out of failed endovascular thrombectomy with a permanent self-expandable stent yielded a favorable outcome in 43% of patients and death in 21%, according to a meta-analysis in the Journal of NeuroInterventional Surgery.


    Read the original article on Medpage Today: Sapien 3 Ultra; Low-Risk TAVR; Pivoting Bioresorbable Tech

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details